Companies / BOC Sciences / Actoxumab
BOC Sciences

Actoxumab | BOC Sciences

Actoxumab is a human monoclonal antibody that binds to C. difficile toxin A and thus preventing toxin from binding to host cells. Actoxumab was developed in conjunction with bezlotoxumab for the treatment of Clostridioides difficile infection.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.